Karnataka sets 1 November medicine-price rule; UAE clinics should audit pharmacy billing

Karnataka Health and Family Welfare Minister UT Khader said hospitals and laboratories must display medicine purchase and selling prices from 1 November 2026, a move UAE clinic operators should treat as a warning on pharmacy billing transparency rather than a foreign regulatory footnote.

The rule, reported by Coastal Digest on 10 October 2026, applies in Karnataka. It does not change UAE law. Its relevance for Dubai, Abu Dhabi and the northern emirates is operational: clinics, hospitals and day-surgery centres already bill medicines into insured and cash episodes, and opaque mark-ups are one of the fastest ways to create payer disputes, patient complaints and regulator attention.

What Karnataka is requiring

Khader said hospitals and laboratories covered by the new requirement must make medicine pricing information available to patients. Bills must show the purchase price and the maximum retail price, according to the Coastal Digest report. The minister said legal action would follow for institutions that violate the requirement.

“Patients must know the price at which medicines are purchased and the price at which they are sold,” Khader said.

The policy target is the margin between acquisition cost and patient charge. Khader linked the concern to high-cost treatment areas, including cancer care, where a single medicine line can shift a bill materially. For UAE operators, the same question appears in another form: whether the medicine charge in the claim, the patient receipt and the regulator-recognised product price can be reconciled without manual explanation.

Why UAE operators should care

In Dubai, Dubai Health Authority (DHA) regulates health facilities and insurance workflows, including eClaimLink standards. In Abu Dhabi and Al Ain, Department of Health Abu Dhabi (DOH) regulates providers and health insurance complaints. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, Ministry of Health and Prevention (MOHAP) remains the relevant federal health regulator for many private-sector licensing and pharmaceutical matters.

The immediate risk sits with CFOs and COOs. Pharmacy revenue is attractive because it is embedded inside visits, procedures and oncology cycles. It is also auditable. A clinic that cannot explain the difference between supplier invoice, approved medicine price, insurer tariff and patient co-payment has a weak control environment.

• Dubai clinics should test whether pharmacy items in the practice-management system match eClaimLink submissions and patient receipts.
• Abu Dhabi providers should review medicine billing pathways for Daman and Thiqa members, especially pre-authorised and high-cost therapies.
• Northern emirates providers should keep current MOHAP or Emirates Drug Establishment product-price references in pharmacy and billing files.
• Cash-pay clinics should prepare a patient-facing explanation for medicine charges before complaints reach a regulator or insurer.

MOHAP’s medicine price-list service gives UAE businesses a practical benchmark. The official service says eligible applicants can request a price list of registered medicines for AED 500, with an average service time of 3 to 5 working days, according to MOHAP service documentation. That is the number UAE finance teams can act on today. If a clinic does not know the applicable UAE price for a medicine, it should obtain the official list or search the Emirates Drug Establishment registered medical product directory before changing patient-facing charges.

What to check before 2027 budgets close

The Karnataka move is unlikely to be copied word for word in the UAE without a local circular. The direction is still clear. Regulators and payers are moving toward price traceability, electronic claims and complaint systems that make unexplained medicine margins easier to spot.

For CFOs, the action is a margin and leakage review by product category. For COOs, it is a workflow review: procurement price, formulary approval, dispensing record, claim code, co-payment and invoice should all point to the same medicine. For CIOs, the question is whether pharmacy, billing and claims systems share one product master, or whether staff are reconciling price files by spreadsheet.

Dubai providers should start with DHA-regulated pharmacy billing and eClaimLink submissions. Abu Dhabi and Al Ain providers should map the same controls against DOH insurance requirements and Daman or Thiqa workflows. Northern emirates providers should verify that MOHAP and Emirates Drug Establishment references are accessible to pharmacy, revenue-cycle and complaints teams.

Patients will compare prices whether regulators require disclosure or not. UAE operators should make sure their own comparison can be defended first. To identify licensed pharmacy providers by emirate, readers can use the UAE Open Healthcare Directory and filter for pharmacy providers.